177 related articles for article (PubMed ID: 20130907)
1. PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Carvalho S; Milanezi F; Costa JL; Amendoeira I; Schmitt F
Virchows Arch; 2010 Mar; 456(3):235-43. PubMed ID: 20130907
[TBL] [Abstract][Full Text] [Related]
2. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
3. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
4. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
5. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
6. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
7. p110α and p110β isoforms of PI3K are involved in protection against H
Singh P; Bano N; Hossain MM; Basit R; Dar MJ
Breast Cancer; 2019 May; 26(3):378-385. PubMed ID: 30499025
[TBL] [Abstract][Full Text] [Related]
8. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
Kim K; Lee HW
Appl Immunohistochem Mol Morphol; 2018; 26(10):740-748. PubMed ID: 28549032
[TBL] [Abstract][Full Text] [Related]
9. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Yip SC; El-Sibai M; Hill KM; Wu H; Fu Z; Condeelis JS; Backer JM
Cell Motil Cytoskeleton; 2004 Nov; 59(3):180-8. PubMed ID: 15468162
[TBL] [Abstract][Full Text] [Related]
11. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
[TBL] [Abstract][Full Text] [Related]
12. Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer.
Cui B; Tao J; Yang Y
Cell Biochem Biophys; 2012 Jan; 62(1):47-54. PubMed ID: 21910030
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of phosphoinositide 3-kinase p110α and p110β isoforms in non-small cell lung cancer.
Lee JS; Lee HW; Lee EH; Park MI; Lee JS; Kim MS; Kim SH; Kim TG; Nam HY; Hwang SW; Park JH
Int J Clin Exp Pathol; 2018; 11(3):1554-1561. PubMed ID: 31938253
[TBL] [Abstract][Full Text] [Related]
14. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
16. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
[TBL] [Abstract][Full Text] [Related]
17. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Zhang C; Xu B; Liu P
Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
[TBL] [Abstract][Full Text] [Related]
19. Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Foukas LC; Berenjeno IM; Gray A; Khwaja A; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11381-6. PubMed ID: 20534549
[TBL] [Abstract][Full Text] [Related]
20. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
